Persistence Market Research has developed an exclusive and in-depth market analysis and forecast for gastrointestinal stromal tumor (GIST). The report covers the expansion of gastrointestinal stromal tumor market across global, regional and local perimeters. The study has been developed to deliver accurate forecast on market size estimations for the assessment period, 2017-2026. From drug development and epidemiology analysis to market entry barriers and changing regulations in the healthcare industry – a range of causative factors for the growth of the global gastrointestinal stromal tumor market have been studied and applied. The impact of these factors is assessed to create presumptive scenarios on how the global gastrointestinal stromal tumor market will expand in the near future.
Companies partaking in the global gastrointestinal stromal tumor market can avail this report to understand the underlying premise of developments in GIST treatments and devise strategies based on the inferences provided in the report. This report serves as a reliable business document for pharmaceutical companies interested in extending their presence in the global gastrointestinal stromal tumor market in the upcoming years.
Analysis and forecast on the global gastrointestinal stromal tumor market has been provided in terms of market size estimations. The report includes a slew of sections reveal the estimated forecast on market and its key segments. The report provides an overview of the overall healthcare industry, addressing the latest trends and breakthrough happenings, which puts forth a connection between the changing healthcare landscape and the evolving marketplace for treatments on gastrointestinal stromal tumors.
Cost structure breakdown, pricing analysis, technology trends, FDA pipeline snapshot, and analysis on drug distribution network has been provided in the report as well. The report further delivers a detailed analysis on the competition landscape in the global gastrointestinal stromal tumor market. Current market standings of emerging players and leading companies are disclosed in this section. This report also reveals the strategic developments of market participants to give insights on competitive business growth towards future market direction.
The report has segmented the global gastrointestinal stromal tumor market on the basis of regions, namely North America, Latin America, Europe, Asia-Pacific excluding Japan (APEJ), Japan, and Middle East and Africa. The report has provided country-specific forecast on the expansion of the overall gastrointestinal stromal tumor market. For extensive analysis, the global market for gastrointestinal stromal tumor is further segmented on the basis of indication, end-use and treatments.
On the basis of indication, the global gastrointestinal stromal tumor market is divided into:
The key end-users in the global market for gastrointestinal stromal tumor include:
Gastrointestinal stromal tumor treatments in the global market are:
A team of analysts, research associates, and subject matter experts has developed this report by tracing the key elements instrumenting the growth in the gastrointestinal stromal tumor market. The report has aggregates the revenues that the market participants have procured through GIST treatments over the recent past. This data has been employed to generate baseline for market size forecasting. Metrics such as Year-on-Year growth rate, absolute dollar opportunities, and compounded annual growth rates, have been used to interpret the forecasted data. The overall market size estimations provided in the report are in US dollars (US$). The scope of the report is to deliver accurate forecast on the future of global gastrointestinal stromal tumor market and enable market participants towards taking informed decisions and developing new strategies for business growth. Companies can avail this report to change their presence in the global GIST market and increase their stake in it.
Gastrointestinal stromal tumors (GISTs) are known as one of the most common mesenchymal tumors in the world. According to the World Health Organization, the estimated incidence rate of gastrointestinal stromal tumors is 14.5 per million, and is prevalent in 129 people from a sample of a million, in the United States. Over the past decade, the understanding, awareness and treatment of GISTs has witnessed a tremendous progress. The pathophysiology of gastrointestinal stromal tumors is being studied actively across medical research institutes and organizations across the globe. Gastrointestinal stromal tumors account for less than one percent of all the GI tract tumors in the world. An exclusive study developed by Persistence Market Research projects that by the end of 2026, the global market for gastrointestinal stromal tumor will be worth over US$ 1.5 Bn. During the forecast period, 2017-2026, the global gastrointestinal stromal tumor market will expand at a robust CAGR of 6.6%.
Stomach Indications to Account for Highest Revenues
Being benign, at most times, gastrointestinal stromal tumors may occur in all parts of the gastrointestinal tract. Yet, the stomach is the most common localization for incidence of gastrointestinal stromal tumors. In terms of indication, the report projects that a majority of treatment and diagnosis for gastrointestinal stromal tumor will be directed to remove the tumor from the stomach. In 2017, nearly 60% of revenues procured in the global gastrointestinal stromal tumor market will be accounted by stomach indication.
Hospitals to Represent Largest End-users
With developments in clinical practice guidelines, the treatment of gastrointestinal stromal tumor is largely executed in hospitals. Extended post-treatment hospitalization period and high morbidity of GISTs continue to fuel the presence of hospitals as end-users in the global gastrointestinal stromal tumor market. By the end of 2026, over US$ 480 Mn worth of revenues will be generated from treating GISTs in hospitals across the globe. Over the forecast period, specialized cancer treatment centers will also emerge as a leading end-user in the global gastrointestinal stromal tumor market.
Chemotherapy to Remain Sought-after Treatment for GISTs
Treatment of gastrointestinal stromal tumor is multidisciplinary, entailing the involvement of medical oncologists, surgeons, radiologist, as well as pathologists. Until now, the role of radiotherapy in treatment of gastrointestinal stromal tumor remains decisively unestablished. For being inoperable, patients suffering from this malignant tumor opt for symptomatic treatments such as conventional chemotherapy. The study projects that over the forecast period, chemotherapy treatment of gastrointestinal stromal tumor across the world will register a strong revenue growth, reflecting a CAGR of 6.3%.
Leading pharmaceuticals companies and medical device manufacturers are actively partaking in the global gastrointestinal stromal tumor market, consolidating its expansion through 2026. Although, the current competition backdrop in the global market for GISTs witnesses the presence of only handful of companies, namely Novartis AG, Sun Pharmaceutical Industries Limited, Pfizer Inc., Bayer Aktiengesellschaft, and NATCO Pharma Limited. These companies are mostly based in the US and Europe. The study further anticipates that by 2026, North America will represent the largest market for gastrointestinal stromal tumors. Unhealthy dietary lifestyles, growing use of food additives, and prevalence of genetic disorders will be mainly responsible in driving the growth of North America’s gastrointestinal stromal tumor market. During the forecast period, the gastrointestinal stromal tumor market in North America is estimated to grow at a CAGR of 6.9%.